This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoff, P. M. Articles by Schmoll, H.-J. Search for Related Content PubMed PubMed Citation Articles by Hoff, P. M. Articles by Schmoll, H.-J.

The Evolution of Fluoropyrimidine Therapy: From Intravenous to Oral

^a Albert Einstein Hospital, São Paulo, Brazil; ^b University of Aberdeen, Aberdeen, UK; ^c Martin-Luther-University Halle-Wittenberg, Halle, Germany

Correspondence: Paulo M. Hoff, M.D., Department of Gastrointestinal Medical Oncology, Centro Paulista de Oncologia, Albert Einstein Hospital, Av. Europa 105, São Paulo, SP-01449-001, Brazil. Telephone: 55-11-3081-2588; Fax: 55-11-3064-6108; e-mail: pmhoff{at}einstein.br

Chemotherapy for advanced colorectal cancer is based on i.v. 5-fluorouracil (5-FU). Numerous attempts have been made to increase the therapeutic benefit of 5-FU through schedule modification and biomodulation, but only modest improvements have been achieved. Capecitabine is an oral fluoropyrimidine that was developed in response to the clinical need for new therapeutic options offering improved efficacy, tolerability, and convenience for patients. Capecitabine was rationally designed to mimic continuous infusion 5-FU. It is rapidly and almost completely absorbed through the gastrointestinal wall and is converted to 5-FU via a three-step enzymatic cascade. 5-FU is generated preferentially in tumor by exploiting the higher activity of thymidine phosphorylase in tumor tissue compared with normal tissue. Results of a randomized, phase II trial led to the selection of a regimen of capecitabine for further clinical development (1,250 mg/m² twice daily for 14 days followed by a 7-day rest period). Subsequently, two large, randomized, phase III trials were conducted to compare capecitabine with i.v. bolus 5-FU/leucovorin ([LV]; Mayo Clinic regimen) in patients with metastatic colorectal cancer. A prospective, integrated analysis of data from the studies showed that capecitabine offers superior activity and an improved safety profile compared with 5-FU/LV. This article summarizes these developments in the treatment of colorectal cancer and assesses the feasibility of replacing i.v. 5-FU-based therapy with oral capecitabine. In addition, retrospective analyses assessing the impact of the dose modification scheme on the efficacy and tolerability of capecitabine are presented, and dose recommendations in special populations are reviewed.

Key Words. Capecitabine • 5-FU • Colorectal cancer • Fluoropyrimidines

This article has been cited by other articles:

				D. Cunningham, B. Sirohi, A. Pluzanska, B. Utracka-Hutka, J. Zaluski, R. Glynne-Jones, P. Koralewski, J. Bridgewater, P. Mainwaring, H. Wasan, et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer Ann. Onc., February 1, 2009; 20(2): 244 - 250. [Abstract] [Full Text] [PDF]

				S. Sturlan, M. Baumgartner, E. Roth, and T. Bachleitner-Hofmann Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells Blood, June 15, 2003; 101(12): 4990 - 4997. [Abstract] [Full Text] [PDF]